[1] ZHU MeijunSUN FangYU ZhenkunCHEN Yang,.Clinical Study on the Combination of Jianpi Yifei Granules and Budesonide Fomotro in the Treatment of Chronic Obstructive Pulmonary Disease [J]. Modern Traditional Chinese Medicine, 2024, (01): 51-55. [doi: 10.13424/j.cnki.mtcm.2024.01.012]
Clinical Study on the Combination of Jianpi Yifei Granules and Budesonide Fomotro in the Treatment of Chronic Obstructive Pulmonary Disease
- Article number:
- 1672-0571(2024)01-0051-05
- Keywords:
- Key words:Jianpi Yifei granules; Budesonide Fomotro; Chronic obstructive pulmonary disease; Disease condition; Airway inflammatory response; Pulmonary function
- ZTFLH:
- R256.1
- Code:
- A
- Abstract:
- Abstract：Objective To explore the therapeutic effect of Jianpi Yifei granules combined with Budesonide Fomotro on chronic obstructive pulmonary disease.Methods All 90 patients were divided into a control group of 45 cases and a treatment group of 45 cases.The control group was treated with nebulized inhalation of budesonide and formoterol.On the basis of the control group，patients in the treatment group received oral administration of Jianpi Yifei granules.Compare the total effective rate，incidence of adverse reactions，and St.Georges Respiratory Scale (SGRQ) between two groups of patients after 3 months of treatment.Detect the induced sputum inflammation indicators ［Prostaglandin E2 (PEG2)，Interleukin 6 (IL-6)，Interleukin 17 (IL-17)］，and major lung function indicators ［Forced expiratory volume per second/forced vital capacity (FEV1/FVC)，FEV1% estimated value，peak expiratory flow (PEF)］ in two groups of patients.Results The total effective rate of the treatment group patients after treatment was 95.56%，which was significantly higher than the 80.00% of the control group，and the difference was statistically significant (P＜0.05).The severity of the condition (SGRQ score) significantly improved in both groups after treatment，and the decrease was more significant in the treatment group (P<0.05).After treatment，the induced sputum PEG2，IL-6，and IL-17 in both groups were significantly reduced，while FEV1/FVC，FEV1% predicted value，and PEF were significantly increased (P<0.05)；The induced sputum PEG2，IL-6，and IL-17 in the treatment group were lower than those in the control group，while FEV1/FVC，FEV1% predicted value，and PEF were higher than those in the control group，with statistically significant differences (P＜0.05).There was no significant difference in the incidence of major adverse reactions between the two groups of drugs (P＞0.05).Conclusion The combination of Jianpi Yifei granules and Budesonide Fomotro is effective in treating chronic obstructive pulmonary disease，helping to control the condition，reduce airway inflammation，and improve lung function in patients.
References:
［1］刘耘充，王红梅，郑丹蕾，等.早期慢性阻塞性肺疾病诊断及治疗进展与争议［J］.中华医学杂志，2021，101(2)：159-164.
［2］陈开宇，江丽萍，陈盛新.慢性阻塞性肺疾病的药物治疗进展［J］.药学实践杂志，2012，30(6)：408-411.
［3］张慧，陈国忠.补肺平喘方联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期(肺肾阳虚证)的疗效观察［J］.中国中医急症，2021，30(4)：710-713.
［4］林甦.益肺健脾颗粒对老年肺脾气虚型COPD患者肺功能的影响［J］.中外医疗，2018，37(35)：90-91，100.
［5］中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)［J］.中华结核和呼吸杂志，2013，36(4)：255-264.
［6］孙明，王蔚文.临床疾病诊断与疗效判断标准［M］.北京：科学技术文献出版社，2010：129-130
［7］Jones P W，Quirk F H，Baveystock C M.The St George sRespiratory Questionnaire［J］.Respirat Med，1991，85(2)：25-31，33-37
［8］李博宇，周梦，翟晓雨，等.慢性阻塞性肺疾病急性加重患者的药物治疗分析［J］.中国临床药理学杂志，2021，37(11)：1433-1435.
［9］刘素香，王婷霄，陈如月，等.化痰理气口服液治疗慢性阻塞性肺疾病急性加重期临床研究［J］.陕西中医药大学学报，2021，44(3)：102-105.
［10］谈翠挽，肖贵华.慢性阻塞性肺疾病急性加重期患者死亡率影响因素研究［J］.现代仪器与医疗，2015，21(3)：7-9.
［11］祁海珍.慢性阻塞性肺疾病呼吸衰竭患者并发低钠血症106例临床分析［J］.中国老年学杂志，2011，31(2)：328-329.
［12］胡颖，郭洁，付伟.益肺定喘汤联合雾化吸入治疗肺肾气虚型COPD预后的机制研究［J］.现代中医药，2021，41(3)：86-89
［13］刘明，杨慧敏，史飞飞，等.补通膏联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病稳定期临床效果［J］.临床误诊误治，2021，34(5)：32-38.
［14］张颢.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的效果探讨［J］.中国实用医药,2022,17(15):123-125.
［15］张元启.布地奈德福莫特罗联合噻托溴铵治疗哮喘——慢阻肺重叠综合征患者的临床疗效及安全性［J］.临床合理用药杂志,2022,15(9):83-86.
［16］王淑远,王万铁,叶环,等.布地奈德福莫特罗吸入剂联合呼吸康复训练治疗慢性阻塞性肺疾病的疗效评估［J］.数理医药学杂志,2022,35(3):424-426.
［17］武艳,穆清爽,王惠欣,等.布地奈德福莫特罗联合三伏贴对稳定期慢性阻塞性肺疾病患者肺功能及中医症候的影响［J］.湖北中医药大学学报,2022,24(1):112-114.
［18］吴娜娜,李梅霞,韩晓环.解毒理肺汤辅助布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期效果及对COX-2、PGE2的影响［J］.新中医,2021,53(10):44-47.
［19］张伶.补肺汤加减治疗肺脾气虚型稳定期慢性阻塞性肺疾病的临床分析［J］.中国医药指南，2020，18(12)：199-200，205.
［20］王中超，李风雷，蒋艳丽.慢性阻塞性肺疾病患者应用中药针灸综合方案效果分析［J］.现代中医药，2021，41(4)：91-94
［21］汤翠英，龚圣雯，庾慧.健脾益肺颗粒抑制肺脾气虚COPD患者气道炎症机制研究［J］.广州中医药大学学报，2018，35(5)：785-789.
［22］邓清洋，孙建，冯晓丽，等.COPD患者血清炎症指标与气道炎症的关系［J］.西部医学，2020，32(1)：69-72.
［23］李霞，荣庆娜，江丽娟，等.慢性阻塞性肺疾病患者IL-8、LTB4、PGE2水平及与肺功能受损严重程度的相关性［J］.中国现代医学杂志，2020，30(18)：18-21.
［24］李霞,荣庆娜,江丽娟,等.慢性阻塞性肺疾病患者IL-8、LTB4、PGE2水平及与肺功能受损严重程度的相关性［J］.中国现代医学杂志,2020,30(18):18-21.
［25］黄惠棉.无创正压通气对慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者sICAM-1、IL-17及PGE2的影响［J］.现代医学与健康研究电子杂志,2020,4(1):72-73.
［26］王萌萌，於海洋，孙雨晴，等.慢性阻塞性肺疾病患者IL-6、IL-8、TNF-α水平与支气管黏膜自噬的相关性分析［J］.临床肺科杂志，2021，26(7)：997-1003.
［27］杨晚霞. 慢性阻塞性肺疾病急性期患者血清IL-6表达水平及临床意义的Meta分析［D］.太原：山西医科大学,2023.
［28］伍桂枝.慢性阻塞性肺疾病与IL-6的关系研究进展［J］.基层医学论坛,2022,26(10):119-121.
［29］孙印，何士杰，景卫革，等.慢性阻塞性肺疾病患者血清IL-21、IL-17、TLR4的表达及临床意义［J］.临床肺科杂志，2020，25(9)：1363-1366.
［30］张琳. 慢性阻塞性肺疾病患者血清IL-17和IL-22的水平及临床意义［D］.南充：川北医学院,2022.
［31］严玉珍.慢性阻塞性肺疾病患者血清IL-21 IL-17 TLR4的表达及临床意义［J］.基层医学论坛,2022,26(1):141-143.
Memo
基金项目：白求恩·医学科学研究基金资助项目（SCZ415BN）